Abstract:As exemplified in patients with Cushing's syndrome, glucocorticoids play an important role in regulating adipose tissue distribution and function, but circulating cortisol concentrations are normal in most patients with obesity. However, human omental adipose stromal cells (ASCs) can generate glucocorticoid locally through the expression of the enzyme 11 beta-hydroxysteroid dehydrogenase (11 beta-HSD) type 1 (11 beta-HSD1), which, in intact cells, has been considered to be an oxoreductase, converting inactive cortisone (E) to cortisol (F). Locally produced F can induce ASC differentiation, but the relationship between 11 beta-HSD1 expression and adipocyte differentiation is unknown. Primary cultures of paired omental (om) and sc ASC and adipocytes were prepared from 17 patients undergoing elective abdominal surgery and cultured for up to 14 d. Expression and activity of 11 beta-HSD isozymes were analyzed together with early (lipoprotein lipase) and terminal (glycerol 3 phosphate dehydrogenase) markers of adipocyte differentiation. On d 1 of culture, 11 beta-HSD1 activity in intact om ASCs exceeded oxoreductase activity in every patient (78.9 +/- 24.9 vs. 15.8 +/- 3.7 [mean +/- SE] pmol/mg per hour, P < 0.001), and in sc ASCs, relative activities were similar (40.6 +/- 12.2 vs. 36.9 +/- 8.8). Conversely, in freshly isolated om adipocytes, reductase activity exceeded dehydrogenase activity (23.6 +/- 1.5 vs. 6.2 +/- 0.8 pmol/mg per hour, P < 0.01). Following 14 d of culture in serum-free conditions with addition of 10 nM insulin (Ctr) or insulin with 100 nM F (+F), lipoprotein lipase/18S RNA levels increased in both the Ctr- and +F-treated ASCs, but glycerol 3 phosphate dehydrogenase increased only in the +F cultures. In both cases, however, 11 beta-HSD1 oxoreductase activity exceeded dehydrogenase activity (Ctr: 53.3 +/- 9.0 vs. 32.4 +/- 10.5, P < 0.05; +F: 65.6 +/- 15.6 vs. 37.1 +/- 11.5 pmol/mg per hour, P < 0.05), despite no significant changes in 11 beta-HSD1 mRNA levels. In sc ASCs, dehydrogenase activity was similar to reductase activity in both Ctr- and +F-treated cells. Type 2 11 beta-HSD expression was undetectable in each case. These data show that in intact, undifferentiated om ASCs, 11 beta-HSD1 acts primarily as a dehydrogenase, but in mature adipocytes oxoreductase activity predominates. Because glucocorticoids inhibit cell proliferation, we postulate that 11 beta-HSD1 activity in uncommitted ASCs may facilitate proliferation rather than differentiation. Once early differentiation is initiated, a "switch" to 11 beta-HSD1 oxoreductase activity generates F, thus promoting adipogenesis. Site-specific regulation of the set-point of 11 beta-HSD1 activity may be an important mechanism underpinning visceral obesity.

11 Beta-Hydroxysteroid Dehydrogenase Type 1 Promotes Differentiation of 3T3-L1 Preadipocyte

11 beta-hydroxysteroid dehydrogenase type 1 promotes differentiation of 3 T 3L 1 preadipocyte 1

Role of 11-Beta-hydroxysteroid Dehydrogenase Type 1 in Differentiation of 3T3-L1 Cells and in Rats with Diet-Induced Obesity

Suppression of 11 Beta-Hydroxysteroid Dehydrogenase Type 1 with Rna Interference Substantially Attenuates 3T3-L1 Adipogenesis

Induction of Adipocyte Hyperplasia in Subcutaneous Fat Depot Alleviated Type 2 Diabetes Symptoms in Obese Mice.

11β-Hydroxysteroid Dehydrogenase Type 1(11β-HSD1) mediates insulin resistance through JNK activation in adipocytes

11Β-Hydroxysteroid Dehydrogenase Type 1 Shrna Ameliorates Glucocorticoid-Induced Insulin Resistance and Lipolysis in Mouse Abdominal Adipose Tissue.

Alteration of 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in a rat model of type 2 diabetes

Resistin Promotes 3T3-L1 Preadipocyte Differentiation.

Essential roles of 11β-HSD1 in regulating brown adipocyte function.

Regulation of 11Β-Hsd1 Expression During Adipose Tissue Expansion by Hypoxia Through Different Activities of NF-κB and HIF-1α.

Interplay Between H6PDH and 11Β-Hsd1 Implicated in the Pathogenesis of Type 2 Diabetes Mellitus.

Efficacious 11Beta-Hydroxysteroid Dehydrogenase Type I Inhibitors in the Diet-Induced Obesity Mouse Model.

The 11Β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Protects Against the Insulin Resistance and Hepatic Steatosis in Db/db Mice.

Ectopic Lipid Deposition Mediates Insulin Resistance in Adipose Specific 11Β-Hydroxysteroid Dehydrogenase Type 1 Transgenic Mice.

Histone Deacetylase 3 Regulates Adipocyte Phenotype at Early Stages of Differentiation

A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells

[Induced differentiation and signaling factor PTEN expression of 3T3-L1 adipocytes]

Hoxa5 Promotes Adipose Differentiation Via Increasing DNA Methylation Level and Inhibiting PKA/HSL Signal Pathway in Mice

Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone (KR-66344)

Specific Reduction of G6PT May Contribute to Downregulation of Hepatic 11Β-Hsd1 in Diabetic Mice.